carfilzomib sold brand name kyprolis anticancer medication acting selective proteasome inhibitor chemically tetrapeptide epoxyketone analog developed onyx pharmaceuticals us food drug administration fda approved july fda approved carfilzomib july use people multiple myeloma received least two prior therapies including treatment bortezomib immunomodulatory therapy lenalidomide demonstrated disease progression within days completion last carfilzomib covalently irreversibly binds inhibits chymotrypsinlike activity proteasome enzyme degrades unwanted cellular proteins carfilzomib displays minimal interactions nonproteasomal targets thereby improving safety profiles inhibition proteasomemediated proteolysis results buildup polyubiquitinated proteins may cause cell cycle arrest apoptosis inhibition tumor carfilzomib derived epoxomicin natural product shown laboratory craig crews yale university inhibit crews laboratory subsequently invented specific derivative epoxomicin named licensed proteolix inc scientists proteolix invented new distinct compound potential use drug humans known carfilzomib proteolix advanced carfilzomib multiple phase ii clinical trials including pivotal phase clinical trial designed seek accelerated clinical trials carfilzomib continue onyx pharmaceuticals acquired proteolix january fda granted carfilzomib fasttrack status allowing onyx initiate rolling submission new drug application december fda granted onyx standard review new drug application submission based study openlabel singlearm phase iib trial trial evaluated heavilypretreated patients relapsed refractory multiple myeloma received least two prior therapies including bortezomib either thalidomide initial approval based response data demonstrating overall survival benefit demonstrated endeavor trial approved singlearm phase ii trial carfilzomib patients relapsed refractory multiple myeloma showed singleagent carfilzomib demonstrated clinical benefit rate patients evaluated overall response rate median duration response months fda approval carfilzomib based results phase ii trial carfilzomib overall response rate among patients relapsed andor refractory multiple myeloma previously received bortezomib study also included bortezomibtreated cohort results reported study also found prolonged carfilzomib treatment tolerable approximately patients continuing treatment beyond one year trial smaller study originally designed investigate impact carfilzomib treatment relationship bortezomib treatment less heavily pretreated prior regimens phase ii trial assessed safety pharmacokinetics pharmacodynamics efficacy carfilzomib patients multiple myeloma varying degrees renal impairment nearly patients refractory bortezomib lenalidomide demonstrated pharmacokinetics safety influenced degree baseline renal impairment carfilzomib tolerable demonstrated another phase ii trial patients relapsed andor refractory multiple myeloma carfilzomib combination lenalidomide dexamethasone demonstrated overall response rate phase ii trial multiple myeloma solid tumors showed promising phase ii trials carfilzomib common grade higher treatmentemergent adverse events hematologic toxicity thrombocytopenia anemia lymphopenia neutropenia pneumonia fatigue frontline phase iii study combination carfilzomib lenalidomide lowdose dexamethasone highly active well tolerated permitting use full doses extended time newly diagnosed multiple myeloma patients limited need dose modification responses rapid improved time reaching good partial furthermore gastrointestinal disturbances including diarrhea nausea non hematologic group side effects commonly reported proteasome additionally cardiovascular toxicity may outcome carfilzomib treatment due effects proteasomes thus patient evaluation risk assessment prior initiation therapy carfilzomib phase iii confirmatory clinical trial known aspire trial compared carfilzomib lenalidomide dexamethasone krd versus lenalidomide dexamethasone rd patients relapsed multiple myeloma found improved progressionfree survival overall survival treatment discontinuation adverse effects occurred less frequently krd arm events included thrombocytopenia hypertension heart carfilzomib costs approximately per httpsenwikipediaorgwikicarfilzomib